The Epstein-Barr virus lytic protein BZLF1 as a candidate target antigen for vaccine development

Cancer Immunology Research

Volumn 3, Issue 7, 2015, Pages 727-794

  Hartlage, Alex S ^a   Liu, Tom ^a   Patton, John T ^b   Garman, Sabrina L ^a   Zhang, Xiaoli ^c   Kurt, Habibe ^c   Lozanski, Gerard ^c   Lustberg, Mark E ^c   Caligiuri, Michael A ^a,b   Baiocchi, Robert A ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; IMMEDIATE EARLY PROTEIN BZLF1; RECOMBINANT PROTEIN; VACCINE; BZLF1 PROTEIN, HERPESVIRUS 4, HUMAN; DNA VACCINE; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL EXPANSION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG TARGETING; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; IN VITRO STUDY; LYMPHOPROLIFERATIVE DISEASE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIMARY TUMOR; SURVIVAL; T LYMPHOCYTE; ANIMAL; CD8+ T LYMPHOCYTE; IMMUNOLOGY; SCID MOUSE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY, CELLULAR; MICE; MICE, SCID; TRANS-ACTIVATORS; VACCINES, DNA;

EID: 84961875543     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0242     Document Type: Article

References (48)

1. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-92.
2. Joseph AM, Babcock GJ, Thorley-Lawson DA. EBV persistence involves strict selection of latently infected B cells. J Immunol 2000;165:2975-81.
3. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity 1998;9:395-404.
4. Miller G. Immortalization of human lymphocytes by Epstein-Barr virus. Yale J Biol Med 1982;55:305-10.
5. Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol 1992;66:122-31.
6. Tan LC, Gudgeon N, Annels NE, Hansasuta P, O'Callaghan CA, Rowland-Jones S, et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 1999;162:1827-35.
7. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003;31:145-55.
8. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009;114:4002-8.
9. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 2010;33:983-90.
10. Comoli P, De Palma R, Siena S, Nocera A, Basso S, Del Galdo F, et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol 2004;15:113-7.
11. Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W, et al. Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 2013;31:39-48.
12. Duraiswamy J, Sherritt M, Thomson S, Tellam J, Cooper L, Connolly G, et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 2003;101:3150-6.
13. Lutzky VP, Corban M, Heslop L, Morrison LE, Crooks P, Hall DF, et al. Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine. J Virol 2010;84:407-17.
14. Ruiss R, Jochum S, Wanner G, Reisbach G, Hammerschmidt W, Zeidler R. A virus-like particle-based Epstein-Barr virus vaccine. J Virol 2011;85:13105-13.
15. Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Leonard P, Moreels A, et al. Recombinant gp350 vaccine for infectiousmononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2007;196:1749-53.
16. Rooney CM, Rowe DT, Ragot T, Farrell PJ. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol 1989;63:3109-16.
17. Countryman J, Jenson H, Seibl R, Wolf H, Miller G. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol 1987;61:3672-9.
18. Farrell PJ, Rowe DT, Rooney CM, Kouzarides T. Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus Ap-1 site and is related to CFos. EMBO J 1989;8:127-32.
19. Fixman ED, Hayward GS, Hayward SD. Replication of Epstein-Barrvirus orilyt - lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays. J Virol 1995;69:2998-3006.
20. Morrison TE, Mauser A, Klingelhutz A, Kenney SC. Epstein-Barr virus immediate-early protein BZLF1 inhibits tumor necrosis factor alphainduced signaling and apoptosis by downregulating tumor necrosis factor receptor 1. J Virol 2004;78:544-9.
21. Morrison TE, Mauser A, Wong A, Ting JPY, Kenney SC. Inhibition of IFNgamma signaling by an Epstein-Barr virus immediate-early protein. Immunity 2001;15:787-99.
22. Zuo JM, Thomas WA, Haigh TA, Fitzsimmons L, Long HM, Hislop AD, et al. Epstein-Barr virus evades CD4 (+) T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2. Plos Pathog 2001;7:e1002455.
23. Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 2011;85:165-77.
24. Bogedain C, Wolf H, Modrow S, Stuber G, Jilg W. Specific cytotoxic Tlymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr-Virus. J Virol 1995;69:4872-9.
25. Precopio ML, Sullivan JL, Willard C, Somasundaran M, Luzuriaga K. Differential kinetics and specificity of EBV-specific CD4 (+) and CD8 (+) T cells during primary infection. J Immunol 2003;170:2590-8.
26. Scherrenburg J, Piriou ER, Nanlohy NM, van Baarle D. Detailed analysis of Epstein-Barr virus-specific CD4+ and CD8+ T cell responses during infectious mononucleosis. Clin Exp Immunol 2008;153:231-9.
27. Baiocchi RA, Ward JS, Carrodeguas L, Eisenbeis CF, Peng R, Roychowdhury S, et al. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. J Clin Invest 2001;108:887-94.
28. Bosma GC, Fried M, Custer RP, Carroll A, Gibson DM, Bosma MJ. Evidence of functional lymphocytes in some (Leaky) SCID mice. J Exp Med 1988;167:1016-33.
29. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune-system to mice with severe combined immunodeficiency. Nature 1988;335:256-9.
30. Rowe M, Young LS, Crocker J, Stokes H, Henderson S, Rickinson AB. Epstein-Barr-Virus (EBV)-associated lymphoproliferative disease in the SCID mouse model - implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 1991;173:147-58.
31. Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR. Cell-lines for the production of recombinant adenoassociated virus. Hum Gene Ther 1995;6:1329-41.
32. Clark KR, Sferra TJ, Johnson PR. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther 1997;8:659-69.
33. Clark KR, Liu XL, McGrath JP, Johnson PR. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther 1999;10:1031-9.
34. Clark KR. Recent advances in recombinant adeno-associated virus vector production. Kidney Int 2002;61:S9-15.
35. Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood 2011;117:4530-41.
36. Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, et al. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 1998;64:358-67.
37. Baiocchi RA, Caligiuri MA. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in SCID/SCID mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc Natl Acad Sci U S A 1994;91:5577-81.
38. Fuzzati-Armentero MT, Duchosal MA. hu-PBL-SCID mice: an in vivo model of Epstein-Barr virus-dependent lymphoproliferative disease. Histol Histopathol 1998;13:155-68.
39. Keating S, Prince S, Jones M, Rowe M. The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J Virol 2002;76:8179-88.
40. Porcu P, Eisenbeis CF, Pelletier RP, Davies EA, Baiocchi RA, Roychowdhury S, et al. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8 (+) T-cell restoration. Blood 2002;100:2341-8.
41. Tary-Lehmann M, Saxon A. Human mature T cells that are anergic in vivo prevail in SCID mice reconstituted with human peripheral blood. J Exp Med 1992;175:503-16.
42. Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001;97:835-43.
43. Khanim F, Yao QY, Niedobitek G, Sihota S, Rickinson AB, Young LS. Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood 1996;88:3491-501.
44. Farrell PJ. Role for HLA in susceptibility to infectious mononucleosis. JClin Invest 2007;117:2756-8.
45. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996;88:202-10.
46. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or flt3-ligand. Cancer Res 2000;60:3239-46.
47. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004;64:6337-43.
48. Lustberg ME, Pelletier RP, Porcu P, Martin SI, Quinion CD, Geyer SM, et al. Human leukocyte antigen type and posttransplant lymphoproliferative disorder. Transplantation 2015;99:1220-5.